Related Experiment Video
Updated: Jun 29, 2025

Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
Published on: October 4, 2021
Young human plasma-derived extracellular vesicles rescue and reactivate IL-1β and TNF-α treated chondrocytes
Rongjie Wu1, Yu Xie1, Yujie Peng1
1Department of Orthopedics, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510000, PR China; Shantou University Medical College, Shantou, Guangdong Province, 515000, PR China.
Abstract:
Osteoarthritis (OA) is a degenerative disease that affects millions of individuals worldwide. Despite its prevalence, the exact causes and mechanisms behind OA are still not fully understood, resulting in a lack of effective treatments to slow down or halt disease progression. Recent research has discovered that extracellular vesicles (EVs) present in the circulation of young mice have a remarkable ability to activate musculoskeletal stem cells in elderly mice. Conversely, EVs derived from elderly mice do not exhibit the same potential, indicating that EVs obtained from young individuals may hold promise to activate aging cells in degenerative tissue. However, it remains unknown whether EVs derived from young individuals can also address cartilage degeneration caused by aging. In this study, we first evaluated EVs derived from young human plasma (YEVs) and EVs derived from old human plasma (OEVs) in an in vitro experiment using chondrocytes. The results revealed that YEVs effectively stimulated chondrocyte proliferation and migration, while OEVs from old plasma did not exhibit a similar effect. Given that OA represents a more complex inflammatory microenvironment, we further determine whether the benefits of YEVs on chondrocytes can be maintained in this context. Our findings indicate that YEVs have the ability to positively regulate chondrocyte function and protect them against apoptosis induced by IL-1β and TNF-α in an in vitro OA model. Furthermore, we discovered that lyophilized EVs could be stored under mild conditions without any alterations in their physical characteristics. Considering the exceptional therapeutic effects and the wide availability of EVs from young plasma, they hold significant promise as a potential approach to activate chondrocytes and promote cartilage regeneration in early-stage OA.
Insights
Extracellular vesicles (EVs) from young plasma activate aging chondrocytes, promoting cartilage repair in osteoarthritis. These young EVs (YEVs) offer a promising therapeutic strategy for early-stage osteoarthritis by enhancing cell function and survival.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Cell Biology
Background:
- Osteoarthritis (OA) is a widespread degenerative joint disease with limited effective treatments.
- Extracellular vesicles (EVs) from young sources show potential in activating aged cells.
- The efficacy of young EVs in addressing age-related cartilage degeneration in OA is not yet established.
Purpose of the Study:
- To investigate the potential of extracellular vesicles (EVs) derived from young human plasma (YEVs) to treat osteoarthritis.
- To compare the effects of YEVs and old human plasma-derived EVs (OEVs) on chondrocytes in vitro.
- To assess the therapeutic benefits of YEVs in an in vitro model of osteoarthritis.
Main Methods:
- In vitro evaluation of YEVs and OEVs on human chondrocytes.
- Assessment of chondrocyte proliferation, migration, and apoptosis in an osteoarthritis model.
- Investigation of YEV stability after lyophilization and storage.
Main Results:
- YEVs significantly enhanced chondrocyte proliferation and migration compared to OEVs.
- YEVs protected chondrocytes against apoptosis induced by inflammatory factors (IL-1β and TNF-α) in an OA model.
- Lyophilized YEVs maintained their physical characteristics during storage.
Conclusions:
- YEVs demonstrate significant therapeutic potential for activating chondrocytes and promoting cartilage regeneration.
- YEVs show promise for treating early-stage osteoarthritis, even in inflammatory conditions.
- The stability of lyophilized YEVs supports their potential for clinical application.

